Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

BRCA1/2 Mutation × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1164 Neoplasms 927 Carcinoma, Non-Small-Cell Lung 771 Prostatic Neoplasms 686 Colorectal Neoplasms 523 Lung Neoplasms 500 Neoplasm Metastasis 383 Multiple Myeloma 371 Leukemia, Myeloid, Acute 353 Ovarian Neoplasms 335 Melanoma 318 Pancreatic Neoplasms 294 Squamous Cell Carcinoma of Head and Neck 263 Recurrence 253 Carcinoma, Hepatocellular 241 Brain Neoplasms 240 Stomach Neoplasms 230 Glioblastoma 213 Lymphoma 211 Uterine Cervical Neoplasms 209 Endometrial Neoplasms 205 Head and Neck Neoplasms 203 Precursor Cell Lymphoblastic Leukemia-Lymphoma 199 Urinary Bladder Neoplasms 198 Triple Negative Breast Neoplasms 198 Carcinoma, Renal Cell 186 Leukemia, Lymphocytic, Chronic, B-Cell 173 Hematologic Neoplasms 170 Glioma 169 Lymphoma, Non-Hodgkin 166

Interventions

rocakinogene sifuplasmid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04367675 2026-02-23

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting

BRCA1/2 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡